Table 3 Association of anticoagulant use (vs. none) after atrial fibrillation diagnosis with cardiovascular events, by sex, among elderly participants in the MarketScan database (2007–2015)
Outcome | Men | Women | p value for multiplicative interaction | ICR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Model 1† | Model 2†† | Model 1† | Model 2†† | |||||||
Anticoagulant | Anticoagulant | Anticoagulant | Anticoagulant | Anticoagulant | Anticoagulant | Anticoagulant | Anticoagulant | |||
− | + | − | + | − | + | − | + | |||
Heart failure | ||||||||||
Events/N | 4020/64,656 | 5154/62,653 | 4020/64,656 | 5154/62,653 | 4093/72,956 | 4461/57,975 | 4093/72,956 | 4461/57,975 | 0.003 | 0.076 |
HR (95% CI) | 1 (ref.) | 1.17 (1.11, 1.22) | 1 (ref.) | 1.05 (1.01, 1.10) | 1 (ref.) | 1.26 (1.20, 1.31) | 1 (ref.) | 1.13 (1.08, 1.18) | ||
Stroke | ||||||||||
Events/N | 1526/64,884 | 1461/62,898 | 1526/64,884 | 1461/62,898 | 2341/73,149 | 1906/58,186 | 2341/73,149 | 1906/58,186 | 0.11 | 0.068 |
HR (95% CI) | 1 (ref.) | 0.84 (0.78, 0.90) | 1 (ref.) | 0.83 (0.77, 0.90) | 1 (ref.) | 0.91 (0.86, 0.97) | 1 (ref.) | 0.91 (0.85, 0.97) | ||
Major bleeding | ||||||||||
Events/N | 2154/63,733 | 4100/63,878 | 2154/63,733 | 4100/63,878 | 2279/70,318 | 3855/60,944 | 2279/70,318 | 3855/60,944 | 0.13 | 0.056 |
HR (95% CI) | 1 (ref.) | 1.24 (1.18, 1.30) | 1 (ref.) | 1.28 (1.22, 1.35) | 1 (ref.) | 1.29 (1.23, 1.36) | 1 (ref.) | 1.35 (1.28, 1.42) | ||